The use of PET/CT in prostate cancer

[1]  B. Tombal,et al.  "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer. , 2017, European urology.

[2]  B. Hadaschik,et al.  18F‐PSMA‐1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer , 2017, Clinical genitourinary cancer.

[3]  Pawan K Gupta,et al.  68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study , 2017, The Journal of Nuclear Medicine.

[4]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[5]  D. Lin,et al.  Role of radical prostatectomy in metastatic prostate cancer: A review. , 2017, Urologic oncology.

[6]  Bernd J. Krause,et al.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study , 2017, The Lancet.

[8]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[9]  H. Saji,et al.  Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[10]  James M. Kelly,et al.  Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  A. Rezaee,et al.  18F-NaF-PET/CT and 99mTc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer. , 2016, Seminars in nuclear medicine.

[12]  M. Schwaiger,et al.  Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. , 2016, European urology.

[13]  C. Stief,et al.  68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. , 2016, European urology.

[14]  E. Plimack,et al.  Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. , 2016, The Lancet. Oncology.

[15]  M. Picchio,et al.  New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. , 2016, European urology.

[16]  P. Choyke,et al.  Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[17]  M. Schwaiger,et al.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. , 2016, The Journal of urology.

[18]  M. Pomper,et al.  PSMA‐targeted imaging of prostate cancer: the best is yet to come , 2016, BJU international.

[19]  D. Schuster,et al.  Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Steve Y. Cho,et al.  PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer , 2016, Molecular Imaging and Biology.

[21]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[22]  Ji-gang Yang,et al.  The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis , 2016, Acta Radiologica.

[23]  R. Knuechel,et al.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  M. Ferrari,et al.  18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  H. Heinzer,et al.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. , 2016, European urology.

[26]  K. Pienta,et al.  PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT? , 2016, Clinical genitourinary cancer.

[27]  H. Fujimoto,et al.  Diagnostic performance and safety of NMK36 (trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid)-PET/CT in primary prostate cancer: multicenter Phase IIb clinical trial. , 2016, Japanese journal of clinical oncology.

[28]  Steve Y. Cho,et al.  Comparison of Prostate-Specific Membrane Antigen–Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[29]  C. Ritter,et al.  Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga‐PSMA‐positron emission tomography/computerized tomography , 2015, The Prostate.

[30]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[31]  U. Haberkorn,et al.  68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  G. Aras,et al.  The role of 18F–NaF PET/CT in metastatic bone disease , 2015, Journal of bone oncology.

[33]  Nassir Navab,et al.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. , 2015, European Urology.

[34]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[35]  Stephan G. Nekolla,et al.  68Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer , 2015, Abdominal Imaging.

[36]  Toby C. Cornish,et al.  18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[37]  Pierre Mozer,et al.  Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. , 2015, European urology.

[38]  A. García-Vicente,et al.  Clinical utility of 18F‐fluorocholine positron‐emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study , 2015, BJU international.

[39]  E. Demirci,et al.  Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging , 2015, Nuclear medicine communications.

[40]  A. Drzezga,et al.  Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer , 2015, Molecular Imaging and Biology.

[41]  D. Rubello,et al.  11C-Choline PET/CT Identifies Osteoblastic and Osteolytic Lesions in Patients with Metastatic Prostate Cancer , 2015, Clinical nuclear medicine.

[42]  M. Schwaiger,et al.  Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.

[43]  Esther Mena,et al.  Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer , 2015, Molecular Imaging and Biology.

[44]  J. Bernhard,et al.  Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. , 2015, European urology.

[45]  Rajiv Kumar,et al.  Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. , 2015, Clinical nuclear medicine.

[46]  V. Drendel,et al.  Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only , 2015, Strahlentherapie und Onkologie.

[47]  T. Joensuu,et al.  Planning of External Beam Radiotherapy for Prostate Cancer Guided by PET/CT. , 2015, Current radiopharmaceuticals.

[48]  G. Delost,et al.  Supplementary Table 1 , 2015 .

[49]  F. Zattoni,et al.  Comparison between conventional imaging (abdominal–pelvic computed tomography and bone scan) and [18F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis , 2015, Scandinavian journal of urology.

[50]  E. Hindié,et al.  Comparative effectiveness of [18F]‐fluorocholine PET‐CT and pelvic MRI with diffusion‐weighted imaging for staging in patients with high‐risk prostate cancer , 2015, The Prostate.

[51]  F. Montorsi,et al.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. , 2015, European urology.

[52]  R. Jeraj,et al.  Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. , 2015, American journal of nuclear medicine and molecular imaging.

[53]  M. H. Poulsen,et al.  Spine metastases in prostate cancer: comparison of technetium‐99m‐MDP whole‐body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT , 2014, BJU international.

[54]  Ronald C. Chen,et al.  Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  C. Nanni,et al.  Anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease , 2014, The Journal of Nuclear Medicine.

[56]  D. Amadori,et al.  Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone , 2014, Oncotarget.

[57]  S. Fanti,et al.  Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging 11C-Choline PET/CT Scan Before Salvage Radiation Therapy? , 2014, The Journal of Nuclear Medicine.

[58]  F. Montorsi,et al.  Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. , 2014, European urology.

[59]  A. Buck,et al.  Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  A. Aksenov,et al.  Sensitivity and specificity of PET/CT regarding the detection of lymph node metastases in prostate cancer recurrence , 2014, SpringerPlus.

[61]  P. Albers,et al.  MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy , 2014, European Radiology.

[62]  M. Scorsetti,et al.  What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients? , 2014, Acta oncologica.

[63]  M. Schwaiger,et al.  Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT , 2014, European Radiology.

[64]  Serge K. Lyashchenko,et al.  A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. , 2014, The Journal of urology.

[65]  F. Bowman,et al.  Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. , 2014, The Journal of urology.

[66]  A. Kopp-Schneider,et al.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[67]  J. Cheville,et al.  Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. , 2014, The Journal of urology.

[68]  R. Coleman,et al.  Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.

[69]  Bettina M. Gramer,et al.  Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[70]  M. Picchio,et al.  11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[71]  P. Choyke,et al.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. , 2014, Radiology.

[72]  F. Fazio,et al.  11C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy , 2014, The Journal of Nuclear Medicine.

[73]  Adam T Froemming,et al.  Detection of Recurrent Prostate Cancer After Radical Prostatectomy: Comparison of 11C-Choline PET/CT with Pelvic Multiparametric MR Imaging with Endorectal Coil , 2014, The Journal of Nuclear Medicine.

[74]  G. Tomasi,et al.  Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer , 2014, Nuclear medicine communications.

[75]  F. M. van der Zant,et al.  A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer , 2013, Nuclear medicine communications.

[76]  V. Ambrosini,et al.  The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option? , 2013, Nuclear medicine communications.

[77]  C. Nanni,et al.  The Role of 11C-Choline PET Imaging in the Early Detection of Recurrence in Surgically Treated Prostate Cancer Patients With Very Low PSA Level <0.5 ng/mL , 2013, Clinical nuclear medicine.

[78]  I. Jambor,et al.  In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.

[79]  R. Fietkau,et al.  Protocol-based image-guided salvage brachytherapy , 2013, Strahlentherapie und Onkologie.

[80]  D. Rubello,et al.  11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT: A Sequential PET/CT Study , 2013, Clinical nuclear medicine.

[81]  J. McConathy,et al.  Radiolabeled Amino Acids for Oncologic Imaging , 2013, The Journal of Nuclear Medicine.

[82]  L. Bachmann,et al.  The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. , 2013, European urology.

[83]  Mohsen Beheshti,et al.  Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics , 2013, The Journal of Nuclear Medicine.

[84]  P. Muzzio,et al.  Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. , 2013, European urology.

[85]  S. Fürst,et al.  PET/MR in prostate cancer: technical aspects and potential diagnostic value , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[86]  A. Graser,et al.  18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. , 2013, European urology.

[87]  G. Martorana,et al.  The promise of choline-PET/CT in the detection of recurrent prostate cancer: what are the limits of our investigation? , 2013, European urology.

[88]  V. Lowe,et al.  Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. , 2013, The Journal of urology.

[89]  S. Ziegler,et al.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  W. Vach,et al.  [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients , 2012, BJU international.

[91]  T. Ohlsson,et al.  Combined 18F‐fluorocholine and 18F‐fluoride positron emission tomography/computed tomography imaging for staging of high‐risk prostate cancer , 2012, BJU international.

[92]  C. Nanni,et al.  Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. , 2012, European journal of radiology.

[93]  F. Mottaghy,et al.  Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? , 2012, International journal of radiation oncology, biology, physics.

[94]  S. Groshen,et al.  Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer , 2012, Clinical nuclear medicine.

[95]  C. Catalano,et al.  Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). , 2012, European journal of radiology.

[96]  B. Seifert,et al.  Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[97]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[98]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[99]  K. Juhl,et al.  Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion , 2012, The Journal of Nuclear Medicine.

[100]  U. Capitanio,et al.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. , 2011, European urology.

[101]  M. Pomper,et al.  2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.

[102]  G. Giovacchini.  Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[103]  O. Cussenot,et al.  Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[104]  C. Simeone,et al.  Role of 11C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation , 2011, Japanese Journal of Radiology.

[105]  F. Mottaghy,et al.  Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[106]  M. Marzola,et al.  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[107]  F. Mottaghy,et al.  Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. , 2011, European urology.

[108]  S. Larson,et al.  Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen , 2011, Proceedings of the National Academy of Sciences.

[109]  Dan Stoianovici,et al.  Advancements in MR imaging of the prostate: from diagnosis to interventions. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[110]  Cordula Petersen,et al.  [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes , 2011, Radiation oncology.

[111]  M. Schwaiger,et al.  Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[112]  Michael G. Stabin,et al.  SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0* , 2010, The Journal of Nuclear Medicine.

[113]  T. DeGrado,et al.  ORIGINAL ARTICLE: Pilot comparison of 18F‐fluorocholine and 18F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer , 2010, Journal of medical imaging and radiation oncology.

[114]  Satoshi Goshima,et al.  Preoperative detection of prostate cancer: A comparison with 11C‐choline PET, 18F‐fluorodeoxyglucose PET and MR imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[115]  J. Martí-Climent,et al.  Dual Tracer 11C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment , 2010, Molecular Imaging and Biology.

[116]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.

[117]  V. Bettinardi,et al.  Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[118]  Anke M Hövels,et al.  MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. , 2008, The Lancet. Oncology.

[119]  F. Fazio,et al.  11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. , 2008, European urology.

[120]  P. Waldenberger,et al.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[121]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[122]  R. Miralbell,et al.  Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[123]  V. Bettinardi,et al.  [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[124]  S. Kohlfuerst,et al.  The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[125]  F. Fazio,et al.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. , 2007, European urology.

[126]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[127]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[128]  W. Sega,et al.  Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. , 2006, The Journal of urology.

[129]  Aditya Bansal,et al.  Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. , 2006, Nuclear medicine and biology.

[130]  S. Fanti,et al.  11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. , 2006, The Journal of urology.

[131]  U. Metser,et al.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[132]  G. Hutchins,et al.  [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. , 2004, Bioorganic & medicinal chemistry.

[133]  M. Kattan,et al.  Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy , 2004 .

[134]  H. Saji,et al.  Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[135]  M. Goodman,et al.  Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[136]  F Fazio,et al.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.

[137]  G. Blake,et al.  Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics , 2001, Nuclear medicine communications.

[138]  M J Welch,et al.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.

[139]  I. Fogelman,et al.  The role of positron emission tomography in the management of bone metastases , 2000, Cancer.

[140]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[141]  D. Schuster,et al.  Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer , 2017, Clinical nuclear medicine.

[142]  N. V. As,et al.  Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. , 2016, European urology.

[143]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[144]  W. Oyen,et al.  PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[145]  F. Montorsi,et al.  Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. , 2014, Urologic oncology.

[146]  K. Macura,et al.  Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer. , 2014, Urologic oncology.

[147]  I. Castiglioni,et al.  Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[148]  B. Fei,et al.  Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. , 2013, American journal of nuclear medicine and molecular imaging.

[149]  M. Picchio,et al.  [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[150]  M. Pomper,et al.  Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. , 2010, Bioorganic & medicinal chemistry letters.

[151]  G. Glatting,et al.  [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[152]  M. Schwaiger,et al.  The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[153]  R. Coleman,et al.  Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[154]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[155]  M. Blau,et al.  18 F-fluoride for bone imaging. , 1972, Seminars in nuclear medicine.